Cannabis Chart Of The Week: Consensus 2024 EBITDA Estimates Are Still Up 8.4% Despite Downward Revisions
Portfolio Pulse from Viridian Capital Advisors
The article discusses the changes in consensus 2024 EBITDA estimates for cannabis companies, noting a general downward revision of 4.5% year-to-date. Despite this, estimates are still 8.4% above 2023 levels. MariMed saw a significant downward revision, while Trulieve experienced an upward revision. The article highlights the challenges faced by the cannabis sector, including rising costs and capital scarcity, and emphasizes the need for patience among investors.
October 14, 2024 | 3:56 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
MariMed's 2024 EBITDA estimates have been revised downward by 48.3%, indicating significant challenges in revenue and margin expectations.
MariMed's significant downward revision in EBITDA estimates suggests major operational or market challenges, likely leading to negative short-term stock price impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Trulieve's 2024 EBITDA estimates have been revised upward by 23.9%, showing positive expectations for revenue and margin improvements.
Trulieve's upward revision in EBITDA estimates suggests strong operational performance and market position, likely leading to positive short-term stock price impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80